Abdul El-Sayed’s latest comments lit up an already heated debate over gender-affirming care for minors, medical authority, and how far the government should go in drawing lines around treatment. His argument leaned hard on the idea that doctors, patients, and parents should control those decisions, while critics pointed to the stakes involved when children are at the center of the fight.
At a rally at Michigan State University, the Michigan Democratic U.S. Senate candidate defended sex changes for children by framing the issue as a matter of medical judgment, not politics. He also leaned into his own background in medicine, using blunt language to describe the training doctors go through and to argue that healthcare choices belong in the exam room.
“I went to a whole a– medical school, everybody I graduated with also went to whole a– medical school,” El-Sayed said. “And then… they went to whole a– residency. Right? And some of them went to whole a– fellowship. They took whole a– exams to provide whole a– healthcare.”
He doubled down by saying the “expert” decision-makers should be doctors, with parents included when the patient is under 18. In his view, the government should not step in and decide what care can or cannot be provided, especially when a family and a physician believe a treatment is appropriate.
That message fits neatly with the broader pitch he has made on the campaign trail. El-Sayed has leaned on his medical credentials as part of his identity as a candidate, presenting himself as someone who understands healthcare from the inside and who wants to expand access through government-backed coverage.
He has also tied that approach to his support for Medicare-for-all, arguing that if the government is paying the bills, it still should not micromanage treatment decisions. The point, as he put it, is that medical choices should stay with the patient and provider, not be dictated from Washington.
“I don’t think the government gets to have a say about what healthcare is provided in what circumstances and why,” El-Sayed said. “And to me, that is the standard on which we decide how we make healthcare decisions.”
He tried to give that idea a conservative-friendly twist by pointing to the Right to Try Act, which was backed by Republicans and lets terminally ill patients seek experimental treatments after other options are exhausted. His argument was that if conservatives trust patients and doctors in that setting, they should accept the same principle more broadly.
“Because conservatives fought for a very long time for this legislation called ‘Right to Try’ legislation, which is the idea that the government couldn’t tell you [that] you couldn’t have a certain medication,” El-Sayed said.
The clash comes as the Trump administration has moved aggressively to restrict sex-change procedures for minors, including hormone treatment and surgeries. That has added more pressure to hospitals and medical groups, many of which have been forced to reassess policies under legal and political scrutiny.
Federal action has already pushed some major hospitals to stop treating children with these procedures. The debate is not happening in a vacuum either, since research on puberty blockers and cross-sex hormones for minors remains contested and politically explosive.
Supporters of tighter limits say the evidence is too thin and the risks are too serious to ignore. Critics say those arguments are being used to interfere with private medical decisions and to strip families of options they believe are necessary for their children.
That tension is now playing out far beyond Michigan, with international examples also getting pulled into the argument. England’s National Health Service paused cross-sex hormones for older teens after saying the supporting research was weak, adding more fuel to a debate that keeps crossing borders.
El-Sayed’s campaign has defended his medical background and said his credentials are real and relevant. The race now sits at the intersection of healthcare politics, culture-war flashpoints, and the bigger question of who gets the final say when medicine, age, and public policy collide.
